ThalassaX Therapeutics announced that the first patient has been successfully dosed in the U.S. Phase I trial of CS231295. This is an early clinical milestone with potential upside, but no efficacy, safety, or guidance details were provided.
ThalassaX Therapeutics announced that the first patient has been successfully dosed in the U.S. Phase I trial of CS231295. This is an early clinical milestone with potential upside, but no efficacy, safety, or guidance details were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20
